Skip to content
HowShorted

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2020

In 2020, BRAINSTORM CELL THERAPEUTICS INC.'s disclosed short interest ran from 3.66% of shares outstanding on 15 Jan 2020 to 17.12% on 31 Dec 2020, a change of +13.46 percentage points. The year's high was 21.44% on 30 Nov 2020 and its low 2.90% on 14 Feb 2020, averaging 11.65% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.18 days on 30 Sep 2020. Full history: BRAINSTORM CELL THERAPEUTICS INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for BRAINSTORM CELL THERAPEUTICS INC. in 2020

2020 in figures

Start of year
3.66% (15 Jan 2020)
End of year
17.12% (31 Dec 2020)
Change
+13.46 pp
High
21.44% (30 Nov 2020)
Low
2.90% (14 Feb 2020)
Average
11.65%
Highest days to cover
14.18 (30 Sep 2020)
SEC filings marked
5

Every report in 2020

BRAINSTORM CELL THERAPEUTICS INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20203.66%4.29
31 Jan 20203.21%8.08
14 Feb 20202.90%1.00
28 Feb 20204.08%1.0010-K filed
13 Mar 20204.21%1.95
31 Mar 20207.14%2.38
15 Apr 20208.75%5.12
30 Apr 202010.02%8.11
15 May 202010.04%6.1910-Q filed
29 May 20209.57%9.43
15 Jun 202010.72%6.00
30 Jun 202015.00%4.03
15 Jul 202015.00%6.02
31 Jul 202011.09%4.58
14 Aug 202011.41%8.0310-Q filed
31 Aug 202012.33%9.27
15 Sep 202012.16%13.40
30 Sep 202014.36%14.18
15 Oct 202016.10%13.1010-Q filed, results (8-K)
30 Oct 202018.91%4.47
13 Nov 202020.32%12.98
30 Nov 202021.44%1.88
15 Dec 202020.18%6.27
31 Dec 202017.12%6.50

See also: BRAINSTORM CELL THERAPEUTICS INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.